

# **Clinical trial results:**

# A Phase II, Randomized, Double-blind, Placebo-Controlled Multicenter Study to Assess the Efficacy and Safety of MSTT1041A in Patients with Moderate to Severe Atopic Dermatitis

# **Summary**

EudraCT number	2018-003429-27
Trial protocol	DE
Global end of trial date	11 March 2020
Results information	
Result version number	v1 (current)
This version publication date	14 May 2021
First version publication date	14 May 2021

# **Trial information**

Trial identification	
Sponsor protocol code	GS40965
Additional study identifiers	
ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT03747575
WHO universal trial number (UTN)	-

Notes:

Sponsors	
Sponsor organisation name	Hoffmann-La Roche
Sponsor organisation address	Grenzacherstrasse 124, Basel, Switzerland, 4070
Public contact	F. Hoffmann-LaRoche AG, Hoffmann-La Roche, +41 616878333, global.trial_information@roche.com
Scientific contact	F. Hoffmann-LaRoche AG, Hoffmann-La Roche, +41 616878333, global.trial_information@roche.com

Notes:

Paediatric regulatory details	
Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage	
Analysis stage	Final
Date of interim/final analysis	11 March 2020
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	11 March 2020
Was the trial ended prematurely?	No

Notes:

# General information about the trial

Main objective of the trial:

The main objective was to assess the efficacy and safety of MSTT1041A (astegolimab) in participants with moderate to severe atopic dermatitis (AD).

Protection of trial subjects:

All participants are required to sign an Informed Consent Form (ICF).

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	06 February 2019
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

# **Population of trial subjects**

# Subjects enrolled per country

Country: Number of subjects enrolled	Germany: 5
Country: Number of subjects enrolled	Poland: 17
Country: Number of subjects enrolled	United States: 43
Worldwide total number of subjects	65
EEA total number of subjects	22

Notes:

Subjects enrolled per age group	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	61
From 65 to 84 years	4
85 years and over	0

# **Subject disposition**

# Recruitment Recruitment details: Pre-assignment Screening details:

Screening details:	
Adults with moderate or severe atopic	dermatitis
Period 1	
Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Investigator, Subject
Arms	
Are arms mutually exclusive?	Yes
Arm title	Placebo
Arm description:	
Participants received a loading dose of	SC placebo matched to MSTT1041A followed by SC placebo Q4W.
Arm type	Placebo
Investigational medicinal product name	e Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use
Dosage and administration details:	
Administered as a loading dose Week	1, then as four subcutaneous (SC) injections every 4 weeks (Q4W)
Arm title	Treatment
Arm description:	
Participants received a loading dose of of SC MSTT1041A every 4 weeks (Q4V	245 mg of subcutaneous (SC) MSTT1041A, followed by 490 mg V).
Arm type	Experimental
Investigational medicinal product name	e Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection

Dosage and administration details:

Routes of administration

Administered as a 245 mg loading dose Week 1, then as four 490 mg subcutaneous (SC) injections every 4 weeks (Q4W)

EU-CTR publication date: 14 May 2021

Subcutaneous use

Number of subjects in period 1	Placebo	Treatment
Started	32	33
Completed	23	26
Not completed	9	7
Consent withdrawn by subject	6	3
Adverse event, non-fatal	-	1
Lost to follow-up	3	3

# **Baseline characteristics**

# **Reporting groups**

Reporting group title Placebo

Reporting group description:

Participants received a loading dose of SC placebo matched to MSTT1041A followed by SC placebo Q4W.

Reporting group title Treatment

Reporting group description:

Participants received a loading dose of 245 mg of subcutaneous (SC) MSTT1041A, followed by 490 mg of SC MSTT1041A every 4 weeks (Q4W).

Reporting group values	Placebo	Treatment	Total
Number of subjects	32	33	65
Age Categorical			
Units: Participants			
<=18 years	0	0	0
Between 18 and 65 years	30	31	61
>=65 years	2	2	4
Age Continuous			
Units: Years			
arithmetic mean	39.3	39.7	
standard deviation	± 14.4	± 15.2	-
Sex: Female, Male			
Units: Participants			
Female	20	20	40
Male	12	13	25
Race (NIH/OMB)			
Units: Subjects			
American Indian or Alaska Native	0	0	0
Asian	4	0	4
Native Hawaiian or Other Pacific Islander	0	0	0
Black or African American	8	8	16
White	20	25	45
More than one race	0	0	0
Unknown or Not Reported	0	0	0
Ethnicity (NIH/OMB)			
Units: Subjects			
Hispanic or Latino	2	2	4
Not Hispanic or Latino	30	30	60
Unknown or Not Reported	0	1	1

# **End points**

# Reporting group title Placebo Reporting group description: Participants received a loading dose of SC placebo matched to MSTT1041A followed by SC placebo Q4W. Reporting group title Treatment Reporting group description: Participants received a loading dose of 245 mg of subcutaneous (SC) MSTT1041A, followed by 490 mg

Primary: Percent Change of	f Total Eczema Area and Severity Index (EASI) Score
End point title	Percent Change of Total Eczema Area and Severity Index (EASI) Score <sup>[1]</sup>
Final maintain annimition.	<del>-</del>
End point description:	
End point description:  End point type	Primary
	Primary

## Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No formal statistical analyses were performed

of SC MSTT1041A every 4 weeks (Q4W).

End point values	Placebo	Treatment	
Subject group type	Reporting group	Reporting group	
Number of subjects analysed	32	33	
Units: Percentage			
arithmetic mean (standard error)	-58.24 (± 9.092)	-51.47 (± 8.639)	

# Statistical analyses

No statistical analyses for this end point

Secondary: Proportion of Participants who Achieve Investigator's Global Assessment (IGA) Response of 0 or 1				
End point title	Proportion of Participants who Achieve Investigator's Global Assessment (IGA) Response of 0 or 1			
End point description:				
End point type	Secondary			
End point timeframe:				
Baseline, Week 16				

End point values	Placebo	Treatment	
Subject group type	Reporting group	Reporting group	
Number of subjects analysed	32	33	
Units: Percentage			
arithmetic mean (standard error)	-39.43 (± 7.839)	-31.22 (± 7.376)	

# Statistical analyses

No statistical analyses for this end point

# Secondary: Percent Change in Body Surface Area (BSA) with Atopic Dermatitis (AD) Involvement

End point title	Percent Change in Body Surface Area (BSA) with Atopic Dermatitis (AD) Involvement
End point description:	
End point type	Secondary

End point timeframe:		
Baseline, Week 16		

End point values	Placebo	Treatment	
Subject group type	Reporting group	Reporting group	
Number of subjects analysed	32	33	
Units: Percentage			
arithmetic mean (standard error)	-38.87 (± 9.134)	-42.23 (± 8.637)	

# Statistical analyses

No statistical analyses for this end point

# Secondary: Percent Change in Disease Severity as Assessed by SCORing Atopic Dermatitis (SCORAD)

End point title	Percent Change in Disease Severity as Assessed by SCORing
	Atopic Dermatitis (SCORAD)

End point description:

End point type	Secondary
End point timeframe:	
Baseline, Week 16	

End point values	Placebo	Treatment	
Subject group type	Reporting group	Reporting group	
Number of subjects analysed	32	33	
Units: Percentage			
arithmetic mean (standard error)	-39.50 (± 7.202)	-35.45 (± 6.837)	

# Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants with Adverse Events (AE)			
End point title	Percentage of Participants with Adverse Events (AE)		
End point description:			
End point type	Secondary		
End point type End point timeframe:	Secondary		

End point values	Placebo	Treatment	
Subject group type	Reporting group	Reporting group	
Number of subjects analysed	32	33	
Units: Percentage			
number (not applicable)	58.1	41.2	

# Statistical analyses

No statistical analyses for this end point

# **Secondary: Serum Concentrations of MSTT1041A**

End point title Serum Concentrations of MSTT1041A<sup>[2]</sup>

End point description:

End point type Secondary

End point timeframe:

At pre-defined intervals from baseline up to Week 24

# Notes:

[2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Results are specific to the arm that received MSTT1041A

End point values	Treatment		
Subject group type	Reporting group		
Number of subjects analysed	33[3]		
Units: ug/mL			
geometric mean (geometric coefficient of variation)			
Day 1 Visit 2/prior to infusion	9999 (± 9999)		
Week 1 Visit 3/prior to infusion	42.6 (± 34.4)		
Week 4 Visit 5/prior to infusion	37.6 (± 52.5)		
Week 8 Visit 7/prior to infusion	36.6 (± 54.5)		
Week 12 Visit 9/prior to infusion	40.1 (± 60.5)		
Week 16 Visit 11	38.2 (± 76.0)		
Period completion/early discontinuation	7.83 (± 151.2)		

## Notes:

[3] - Summary statistics not reportable for time points where > one-third of samples were not reportable.

# Statistical analyses

No statistical analyses for this end point

Secondary: Incidence of Treatment-Emergent Anti-Drug Antibodies (ADAs)				
End point title	Incidence of Treatment-Emergent Anti-Drug Antibodies (ADAs)			
End point description:				
End point type	Secondary			
End point type End point timeframe:	Secondary			

End point values	Placebo	Treatment	
Subject group type	Reporting group	Reporting group	
Number of subjects analysed	32	33	
Units: Participants	0	1	

# Statistical analyses

No statistical analyses for this end point

Page 10 of 13

## **Adverse events**

# **Adverse events information**

Timeframe for reporting adverse events:

Up to Week 16

Adverse event reporting additional description:

The safety population contained all randomized participants who received at least one dose of study drug. Participants are grouped according to actual treatment received.

Assessment type Non-systematic

# **Dictionary used**

Dictionary name	MedDRA
Dictionary version	23.0

# **Reporting groups**

-	
	I
Reporting group title	IPlacebo
Reporting group title	I lacebo

Reporting group description:

Participants received a loading dose of SC placebo matched to MSTT1041A followed by SC placebo Q4W.

Reporting group title Treatment

Reporting group description:

Participants received a loading dose of 245 mg of subcutaneous (SC) MSTT1041A, followed by 490 mg of SC MSTT1041A every 4 weeks (Q4W).

Serious adverse events	Placebo	Treatment	
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 31 (0.00%)	1 / 34 (2.94%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events			
Vascular disorders			
Aortic aneurysm			
subjects affected / exposed	0 / 31 (0.00%)	1 / 34 (2.94%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Placebo	Treatment	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	8 / 31 (25.81%)	3 / 34 (8.82%)	
Gastrointestinal disorders			
Abdominal pain			

subjects affected / exposed occurrences (all)	2 / 31 (6.45%) 2	0 / 34 (0.00%) 0	
Skin and subcutaneous tissue disorders  Dermatitis atopic  subjects affected / exposed  occurrences (all)	5 / 31 (16.13%) 6	3 / 34 (8.82%) 3	
Infections and infestations  Nasopharyngitis  subjects affected / exposed  occurrences (all)	3 / 31 (9.68%) 5	0 / 34 (0.00%) 0	

# **More information**

# Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

# **Interruptions (globally)**

Were there any global interruptions to the trial? No

# **Limitations and caveats**

None reported